AA-derived drugs, such as prostacyclin analogs (e.g., iloprost and treprostinil) to enhance vasodilation in the BA, or TXA2 receptor antagonists (e.g., seratrodast) to attenuate vasoconstriction in the MCA, or using selective modulators of prostaglandin receptors (e.g., EP4 agonists) for vascular relaxation, and COX inhibitors to reduce vasoconstrictor metabolites while preserving vasodilator prostaglandins can be used in the medication of stroke patients. The gene discussed is PTGER4; the disease is stroke disorder.